BioMarin pares Roctavian spending as it narrows sales focus
Bio Pharma Dive
AUGUST 6, 2024
The company plans to limit sales of the hemophilia gene therapy to the U.S., Italy and Germany, while ending most clinical development work.
Acute lymphocytic leukaemia leads in cell therapy clinical development
Pharmaceutical Technology
JULY 12, 2022
The leading marketed CAR-T cell products, Gilead’s Yescarta (axicabtagene ciloleucel) and Novartis’ Kymriah (tisagenlecleucel), achieved $695m and $587m in sales respectively last year, demonstrating the high potential for sales of successful new cell therapies.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Sandoz bulks up ahead of possible sale with Coalesce buy
pharmaphorum
MARCH 14, 2022
Developing inhaler products that use high-tech delivery devices – which can improve patient convenience and compliance with therapy – is one way to carve out market share and secure better pricing. Sandoz already markets six respiratory products, with almost a dozen in clinical development, according to the generic drugmaker.
Sales 
104
104 
The future of pain medication: are cannabinoids the solution to the opioid epidemic?
Pharmaceutical Technology
JUNE 12, 2023
In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. A promising example includes Vertex Pharmaceuticals’s VX-548, a sodium channel subunit blocker.
Drugs 358
358 
Hookipa partners with Roche for cancer immunotherapy development
Pharmaceutical Technology
OCTOBER 21, 2022
Hookipa Pharma and Roche have signed a strategic partnership and licence agreement for developing HB-700 and another undisclosed arenaviral immunotherapy. Under the deal, Hookipa will carry out research and initial clinical development through Phase Ib for HB-700 to treat KRAS-mutated cancers.
Development 278
278 
Merck agrees to acquire Imago for $1.35bn
Pharmaceutical Technology
NOVEMBER 21, 2022
Imago BioSciences founder and CEO Dr Hugh Rienhoff said: “This agreement leverages Merck’s industry-leading clinical development expertise to maximise the therapeutic potential of bomedemstat while providing important value for shareholders.”.
Clinical Trials 246
246 
GSK to acquire BELLUS Health for $2bn
Pharmaceutical Technology
APRIL 19, 2023
Camlipixant is being assessed in the CALM Phase III clinical development programme, with anticipated regulatory approval and launch in 2026. According to current clinical data, the therapy may reduce cough frequency for RCC patients with a relatively low incidence of dysgeusia by selectively inhibiting P2X3 receptors.
Medicine 243
243 
Betta to commercialise C4 Therapeutics’ CFT8919 in greater China
Pharmaceutical Technology
MAY 31, 2023
Betta chairman and CEO Lieming Ding stated: “The collaboration will further expand Betta’s product pipeline and improve the productivity of the company’s research and development from discovery to clinical development and to commercialisation.”
In-Vivo 130
130 
3BP and Novartis strike licensing agreement for FAP-targeting peptide technology
Pharmaceutical Technology
APRIL 25, 2023
3BP receives an initial payment of $40m, and $425m as development, regulatory and commercial milestone payments. Tiered royalties on net sales are also included in the deal. 3BP continues to hold specific rights to develop its FAP-targeting imaging technology for diagnostic applications.
Licensing 130
130 
Corbus and CSPC Megalith sign licence agreement for antibody drug conjugate
Pharmaceutical Technology
FEBRUARY 14, 2023
upfront payment and eligible for royalties on net sales. It will also receive potential development and regulatory milestone payments of up to $130m along with potential commercial milestone payments of $555m. We look forward to working with CSPC to advance clinical development of this asset and realise its full potential.”
Antibody 130
130 
Ono Pharmaceutical enters research deal with Monash University
Pharmaceutical Technology
JANUARY 16, 2023
Monash University will also receive milestone payments on clinical development and sales progress, along with royalties based on net sales of the products in the future, if the option is exercised by Ono Pharmaceutical under the deal.
Research 130
130 
Gilead partners with MacroGenics for bispecific antibody development
Pharmaceutical Technology
OCTOBER 18, 2022
MacroGenics is also entitled to get payments totalling up to $1.7bn in target nomination, option fees, regulatory, development and commercial milestones. Additionally, Gilead will make tiered royalty payments on global net MGD024 sales and a flat royalty on international net product sales under the two research programmes to MacroGenics.
Antibody 130
130 
Zerion and Insud to develop Dispersome formulations of drugs
Pharmaceutical Technology
AUGUST 30, 2022
Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.
Development 130
130 
Roche Invests $5.3B in Zealand’s Petrelintide, an Obesity Drug Candidate
XTalks
MARCH 17, 2025
The partnership also outlines development milestones of $1.2 billion, primarily linked to initiating Phase III trials for petrelintide as a stand-alone therapy, with sales-based milestones that could push the total value to $5.3
Hormones 59
59 
Poseida and Roche to develop cell therapies for hematologic cancers
Pharmaceutical Technology
AUGUST 4, 2022
The company could also receive a total of up to $6bn in research, development, launch and net sales milestones and other payments, in addition to tiered royalty payments on net product sales, across various programmes.
Development 147
147 
AbbVie begins trials of COVID-19 antibody therapy
pharmaphorum
DECEMBER 16, 2020
AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.
Antibody 98
98 
AbbVie and HotSpot sign partnership for autoimmune disease therapy
Pharmaceutical Technology
DECEMBER 7, 2022
HotSpot is also entitled to get option fees and research and development milestone payments totalling up to $295m. Additionally, AbbVie could make commercial milestone and tiered royalty payments on global net sales in the future to HotSpot.
Development 147
147 
GSK and Wave Life Sciences partner to develop oligonucleotide therapeutics
Pharmaceutical Technology
DECEMBER 14, 2022
Additionally, for WVE-006, GSK will make development and launch milestone payments of up to $225m to Wave, which is also eligible to get up to $300m in milestone payments based on sales. On completion of the first-in-patient clinical trial by Wave, GSK will be in charge of the development and marketing works.
Life Science 162
162 
China’s NMPA approves Vascepa for hypertriglyceridemia
Pharmaceutical Technology
JUNE 2, 2023
Furthermore, Amarin will receive tiered double-digit percentage royalties on the net sales of Vascepa in the territory. As a result of obtaining the NMPA approval, EDDING has to pay $5m as a regulatory milestone payment to Amarin.
Clinical Trials 130
130 
Entrance of novel therapies will drive Niemann-Pick type C disease market growth
Pharmaceutical Technology
JULY 26, 2022
This sales growth will be in line with a steadily increasing disease prevalence and the entrance of novel agents into the market. The three major markets (3MM: the US, Germany and the UK) will increase in market size from $128.35m last year to $188.35m in 2031, at a compound annual growth rate (CAGR) of 3.9%.
Marketing 306
306 
Capricor and Nippon Shinyaku partner for DMD therapy distribution in Japan
Pharmaceutical Technology
FEBRUARY 17, 2023
Capricor will handle the clinical development of CAP-1002 and sell commercial products to Nippon Shinyaku. Additionally, Capricor will receive up to $89m in further development and sales-based milestones, along with a double-digit share of revenue based on product sales.
Gene Therapy 130
130 
Top 10 Largest MedTech Mergers and Acquisitions of the Decade
XTalks
JANUARY 7, 2025
billion Announced : April 2021 Closed : December 2021 Thermo Fisher Scientific, a worldwide supplier of analytical instruments, clinical development solutions, specialty diagnostics, lab, pharmaceutical and biotech services, acquired PPD , a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4
Life Science 105
105 
IQVIA cuts sales guidance as site staff shortages delay execution of deliveries
Outsourcing Pharma
NOVEMBER 9, 2022
IQVIA has reduced its full-year sales guidance in response to factors including bottlenecks created by staff shortages at certain sites.
Sales 52
52 
Assertio to buy commercial-stage biopharmaceutical firm Spectrum
Pharmaceutical Technology
APRIL 25, 2023
Spectrum is a commercial-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel and targeted oncology treatments. The company has its own clinical development organisation equipped with regulatory and data management competencies.
Pfizer acquires ADC pioneer Seagen for $43bn
Pharmaceutical Technology
MARCH 23, 2023
The company also has several promising agents in early clinical development. This figure derives from net product sales in addition to revenues gained from royalties and licensing agreements. Seagen generated almost $2 billion in revenue in 2022, an increase approaching 25% from 2021.
Licensing 147
147 
Merck and Orna partner for RNA technology-based vaccines and therapies
Pharmaceutical Technology
AUGUST 17, 2022
Preclinical data showed the potential of oRNA expression and delivery as a method for advanced development in various areas, including vaccines and oncology treatments. Merck will also make royalty payments on any approved products developed out of the partnership.
RNA 147
147 
Gilead partners with EVOQ for RA and lupus immunotherapies
Pharmaceutical Technology
JANUARY 4, 2023
Under the deal terms, the two companies will work together to advance the preclinical development of RA and lupus immunotherapies. Gilead will be responsible for the clinical development and commercialisation and holds the rights to exclusively license the NanoDisc technology of EVOQ for the product candidates.
Licensing 130
130 
Pfizer and Clear Creek Bio to develop PLpro inhibitors for Covid-19
Pharmaceutical Technology
DECEMBER 7, 2022
Clear Creek Bio is also entitled to receive further potential milestone payments as well as royalties on sales of products in the future. Under the agreement, Pfizer will make an undisclosed upfront payment to Clear Creek Bio.
Development 130
130 
Regeneron and CytomX partner to develop bispecific cancer therapies
Pharmaceutical Technology
NOVEMBER 18, 2022
According to the agreement, CytomX will receive a $30m upfront payment and is eligible to receive up to $2bn in preclinical, clinical, and commercial milestones. The company will also receive tiered global net sales royalties.
Development 130
130 
PLAIO raises €4.3M to revolutionize pharma supply chains with AI-driven planning platform
Outsourcing Pharma
AUGUST 12, 2024
million in an oversubscribed funding round to accelerate its AI-driven sales and operations planning platform designed specifically for the pharmaceutical sector. In a landmark move for the pharmaceutical industry, PLAIO, a pioneering Icelandic tech firm, has secured â4.3
Sales 95
95 
Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
The Pharma Data
MAY 8, 2021
Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1. source Link.
Lacerta partners with Prevail to develop AAV capsids for CNS diseases
Pharmaceutical Technology
AUGUST 24, 2022
Prevail will also handle the complete production, clinical development and marketing activities. Lacerta is entitled to receive an upfront payment as well as development and commercial milestone payments from Prevail.
Development 130
130 
Valneva accelerates Lyme disease vaccine R&D project with Pfizer
pharmaphorum
DECEMBER 4, 2020
Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets. Valneva is paying 30% of development costs and in return Pfizer will pay tiered royalties starting at 19% and will lead late-stage development.
Vaccination 119
119 
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Retatrutide?
Pharmaceutical Technology
FEBRUARY 24, 2023
Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Sales 113
113 
Blackstone funds new trials of Sanofi’s Sarclisa in myeloma
pharmaphorum
MARCH 15, 2022
In return, it will get a royalty on sales if the new version gets approved. It’s an example of a fairly uncommon risk-sharing model, in which an investment group funds a clinical development programme in the hope of a bigger payoff down the line, with rights to the drug staying with the pharma partner.
Trials 97
97 
Lead Pharma signs $308m deal to develop small molecule drugs with Roche
pharmaphorum
NOVEMBER 17, 2020
Based in Oss-Netherlands, Lead will be eligible to receive research funding and pre-clinical milestone payments; total potential payments including research, development, regulatory and sales milestones may add up to 260 million euros, plus royalties on worldwide sales. Roche last year signed a $792.5
Development 72
72 
GSK’s Blujepa Wins FDA Approval as First New Class of Antibiotic for UTIs
XTalks
APRIL 15, 2025
XTALKS WEBINAR: Leveraging AI in Clinical Development to Innovate with Greater Confidence Live and On-Demand: Tuesday, June 3, 2025 , at 10am EDT (4pm CEST / EU-Central) Register for this free webinar to learn how AI-powered technology can uncover potential study design risks by identifying areas of patient burden and complexity.
FDA Approval 66
66 
Regeneron, CytomX announce bispecific therapeutics for cancer collab
pharmaphorum
NOVEMBER 18, 2022
Physician-scientist led biotech Regeneron will be responsible for funding preclinical and clinical development and commercialisation activities, while oncology-focused biopharma CytomX will receive $30 million in an upfront payment , with the potential for up to $2 billion in research, development, regulatory, and sales-based milestones, also.
Antibody 105
105 
Rezvilutamide by Jiangsu Hengrui Medicine for Liver Failure (Hepatic Insufficiency): Likelihood of Approval
Pharmaceutical Technology
JUNE 5, 2023
Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Liver Failure (Hepatic Insufficiency). The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia.
Medicine 100
100 
Rezvilutamide by Jiangsu Hengrui Medicine for Prostate Cancer: Likelihood of Approval
Pharmaceutical Technology
JUNE 5, 2023
Rezvilutamide is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Prostate Cancer. The company is also developing pipeline products for the treatment of cancer, Crohn’s disease, anemia, diabetes, atopic dermatitis, chronic bone disease, blood pressure, and hypercholesterolemia.
Medicine 100
100 
TPG Forms Ellodi Pharmaceuticals to Continue Clinical Development of APT-1011 for Treatment of Eosinophilic Esophagitis
BioTech 365
SEPTEMBER 22, 2020
TPG Capital establishes new entity to continue the development of select clinical assets spun-out of Adare Pharmaceuticals Announcement follows TPG Capital’s sale of Adare Pharmaceuticals’ specialty CDMO pharmaceutical technology and microbiome businesses SAN FRANCISCO & FORT WORTH, Texas–(BUSINESS WIRE)–TPG Capital, … (..)
Idorsia is first to EU market with orexin insomnia drug
pharmaphorum
MAY 3, 2022
Belsomra’s first-to-market advantage in the US hasn’t however translated into big annual sales, which have stayed planted just over the $300 million mark since 2019. Both Belsomra and Dayvigo have box warnings on their labels in the US on daytime functioning, including the ability to drive motor vehicles.
Marketing 97
97 
Risk adjusted net present value: What is the current valuation of Axsome Therapeutics’s Esreboxetine?
Pharmaceutical Technology
FEBRUARY 20, 2023
Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Sales 100
100 
Greenphire's Dave Hine's reflections on DPharm 2023 - and how 'rising tides lift all boats'
Outsourcing Pharma
OCTOBER 20, 2023
Dave Hine is the senior director of sales and engineering at Greenphire. He has been reflecting on his time at DPharm and the collaborative approach to life sciences.
Life Science 85
85 
Let's personalize your content